Subscribe To
springworks therapeutics reports third quarter 2023 financial results and recent business highlights
– PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023 – – On track to report topline d...
November 2, 2023, 10:30 am
springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 ctos annual meeting
– Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools –...
November 1, 2023, 10:30 am
springworks therapeutics: fda decision date ahead
Today we revisit springworks Therapeutics, Inc. for the first time in nearly a year. The company's prim...
July 12, 2023, 3:33 pm
Us fda delays decision on springworks therapeutics' tumor treatment
The U.S. Food and Drug Administration (FDA) has extended its decision for springworks Therapeutics Inc'...
June 5, 2023, 11:04 am
springworks therapeutics announces pdufa date extension for nirogacestat nda
FDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023 STAMFORD, Conn., June 05...
June 5, 2023, 10:30 am
springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 asco annual meeting
– Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools – –...
May 25, 2023, 9:05 pm
springworks therapeutics: pfizer offshoot with interesting pipeline
springworks Therapeutics: Pfizer Offshoot With Interesting Pipeline...
April 14, 2023, 10:25 am
springworks therapeutics announces new england journal of medicine publication of phase 3 defi trial evaluating nirogacestat in adults with desmoid tumors
– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes – – New Dru...
March 8, 2023, 10:05 pm
springworks therapeutics completes submission of new drug application to the fda for nirogacestat for the treatment of adults with desmoid tumors
STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) — springworks Therapeutics, Inc. (Nasdaq: SWTX), a cl...
December 27, 2022, 11:30 am
springworks therapeutics shares jump on hc wainwright bullish pitch
HC Wainwright points out that investors are enthusiastic about springworks Therapeutics Inc (NASDAQ:...
June 13, 2022, 9:14 am
springworks therapeutics to present progress across the company's targeted oncology portfolio at virtual r&d day
-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA's Real-Time Oncology Review (RTOR) Program, Expected in Second ...
June 10, 2022, 6:30 am
Here is why springworks therapeutics jumped 20%
springworks Therapeutics Inc. (NASDAQ: SWTX) stock jumped 20% after the clinical-stage company focusing...
May 27, 2022, 4:13 pm
springworks (swtx) down despite desmoid tumors study meeting goal
springworks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult pa...
May 25, 2022, 1:48 pm
springworks therapeutics: rating buy ahead of mid-year data releases
Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with anti-BCMA antibody Blenrep in relapsed/refracto...
May 2, 2022, 5:42 pm
springworks (swtx) & abbvie unite for multiple myeloma drug
springworks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogace...
December 13, 2021, 1:50 pm
springworks (swtx) & abbvie unite for multiple myeloma drug
springworks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogace...
December 13, 2021, 1:50 pm
springworks (swtx) & abbvie unite for multiple myeloma drug
springworks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogace...
December 13, 2021, 1:50 pm